The University of Pittsburgh has been awarded a $656,560 Project Grant under the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393). The 5-year grant, awarded on August 1, 2024, will support a comprehensive study to characterize oral anticancer medication (OAM) adherence initiation and persistence among patients with hematologic malignancies such as multiple myeloma, chronic myeloid leukemia, and chronic lymphocytic leukemia. The research aims to identify multi-level factors influencing OAM adherence and explore the relationships between adherence and health outcomes including healthcare utilization, quality of life, and survival. The findings will inform the development of targeted, culturally sensitive interventions to improve OAM adherence and cancer outcomes, particularly among at-risk populations. The University of Pittsburgh will lead this mixed-methods, prospective study with a sample of 306 socioeconomically diverse patients prescribed long-term OAM therapy.